On Aug. 6, 2020, Novavax announced a license agreement with Serum Institute of India Private Limited (SIIPL) for the development and commercialization of NVX-CoV2373, Novavaxﾒ COVID-19 vaccine candidate, in low- and middle-income countries (LMIC) and India.

This agreement excludes major upper-middle and high-income countries, for which Novavax continues to retain rights. NVX-CoV2373 is a stable, prefusion protein made using Novavaxﾒ recombinant protein nanoparticle technology and includes Novavaxﾒ proprietary Matrix-Mﾙ adjuvant.